Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PMC

Pharmerica (PMC) Stock Price, News & Analysis

Pharmerica logo

About Pharmerica Stock (NYSE:PMC)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
283,015 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmerica and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PMC Stock News Headlines

GENIUS Act: The Plot to Seize Your Cash?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.tc pixel
Activities of Daily Living for Seniors
Golden Living
See More Headlines

PMC Stock Analysis - Frequently Asked Questions

Pharmerica Co. (NYSE:PMC) issued its quarterly earnings results on Thursday, November, 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by $0.03. The firm had revenue of $595.10 million for the quarter, compared to the consensus estimate of $596.80 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmerica investors own include Cencora (COR), Capitol Federal Financial (CFFN), Bristol Myers Squibb (BMY), Tesla (TSLA), Depomed (DEPO), Inovio Pharmaceuticals (INO) and Bioblast Pharma (ORPN).

Company Calendar

Last Earnings
11/09/2017
Today
9/17/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
N/A
Industry
N/A
Sub-Industry
Health Care Distributors
Current Symbol
NYSE:PMC
CIK
1388195
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:PMC) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners